Advertisement

Topics

FDA Grants Priority Review to Gilead's Fixed-Dose BIC/FTC/TAF HIV Treatment

13:47 EDT 11 Aug 2017 | Drug Discovery Development

The NDA is supported by data from four Phase 3 studies that evaluated the fixed-dose combination among treatment-naïve patients and among virologically suppressed patients.
Contributed Author: 
Gilead Sciences
Topics: 

Original Article: FDA Grants Priority Review to Gilead's Fixed-Dose BIC/FTC/TAF HIV Treatment

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Gilead's Fixed-Dose BIC/FTC/TAF HIV Treatment"

Quick Search
Advertisement